Harmony Biosciences is trading at $39.83, down 4.09%, with the decline appearing primarily tied to biotechnology-sector weakness.
- No clear company-specific announcement or catalyst emerged on September 23, 2026; XBI was down 2.04%.
- Broader risk-off trading coincided with rising crude oil and elevated Treasury yields.
- Previously reported positive acquisition-planning commentary does not directly explain today’s decline.